Linked e-resources
Details
Table of Contents
Contributors; 1 Introduction; Monoclonal Gammopathy of Undetermined Significance; Plasma Cell Myeloma; Plasmacytoma; Monoclonal Immunoglobulin Deposition Diseases; References; 2 Clinical Features, Management, and Therapy of Plasma Cell Neoplasms: What Pathologists Need to Know; Introduction; Clinical Features of Plasma Cell Neoplasms; Diagnostic Evaluation; Detection of Paraproteins and Laboratory Tests; Bone Marrow Aspirate and Biopsy; Imaging Studies; Treatment of Plasma Cell Neoplasms; Supportive Therapy; Prognosis and Clinical Outcomes; Conclusion; References
3 Morphologic and Immunohistochemical Evaluation of Plasma Cell NeoplasmsIntroduction; Normal Bone Marrow Plasma Cells: General Findings and Morphologic Features; Bone Marrow Evaluation in Plasma Cell Myeloma: Diagnostic Considerations and Practical Issues; Plasma Cell Myeloma: Diagnostically Helpful Morphologic Findings; Grading of PCM; Unusual PCM Variants; Small Lymphocyte-Like PCM; Nonsecretory PCM; Plasma Cell Leukemia (PCL); Primary Amyloidosis and PCM with Associated Amyloidosis; PCM with Associated Crystal Storing Histiocytosis; PCM with Myelofibrosis
Association of Plasma Cell Myeloma with Other MalignanciesImmunohistochemical Evaluation of Plasma Cell Neoplasms; CD138; MUM1; CLIMP-63; Immunoglobulin Heavy and Light Chains; CD20; PAX5; CD56; Cyclin D1; References; 4 Cytogenetics of Plasma Cell Neoplasms; Introduction; Numerical Chromosome Aberrations; Primary Structural Aberrations in PC Disorders; Cytogenetic Aberrations Present in MGUS; Cytogenetic Aberrations Present in Smoldering MM; Cytogenetic Aberrations in Symptomatic Myeloma; Chromosome 13 Aberrations; Deletions of 17p13; Chromosome 1p Deletions; 1q21 Amplification
The Origin of 1q21 Copy Number IncreasesClonal Evolution to Cytogenetically Defined High-Risk Disease; Myelodysplastic Clones; Conclusion; Acknowledgments; References; 5 Flow Cytometric Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms; FCM for Diagnosis of PCN; FCM for Identification of Biomarkers; FCM for MRD Monitoring; FCM as a Differential Diagnosis; FCM for Identification of Therapeutic Target; Summary; References; 6 Renal Manifestations of Plasma Cell Neoplasms; Introduction; Light Chain Cast Nephropathy; Light Chain Proximal Tubulopathy
Monoclonal Ig Deposition DiseaseRenal Amyloidosis; Monoclonal Gammopathy of Renal Significance; Immunofluorescence; Electron Microscopy; Tubulointerstitial Nephritis, Monoclonal Light Chain Mediated; Waldenstrom Macroglobulinemia-Associated Glomerulopathy; Conclusion; References; Index
3 Morphologic and Immunohistochemical Evaluation of Plasma Cell NeoplasmsIntroduction; Normal Bone Marrow Plasma Cells: General Findings and Morphologic Features; Bone Marrow Evaluation in Plasma Cell Myeloma: Diagnostic Considerations and Practical Issues; Plasma Cell Myeloma: Diagnostically Helpful Morphologic Findings; Grading of PCM; Unusual PCM Variants; Small Lymphocyte-Like PCM; Nonsecretory PCM; Plasma Cell Leukemia (PCL); Primary Amyloidosis and PCM with Associated Amyloidosis; PCM with Associated Crystal Storing Histiocytosis; PCM with Myelofibrosis
Association of Plasma Cell Myeloma with Other MalignanciesImmunohistochemical Evaluation of Plasma Cell Neoplasms; CD138; MUM1; CLIMP-63; Immunoglobulin Heavy and Light Chains; CD20; PAX5; CD56; Cyclin D1; References; 4 Cytogenetics of Plasma Cell Neoplasms; Introduction; Numerical Chromosome Aberrations; Primary Structural Aberrations in PC Disorders; Cytogenetic Aberrations Present in MGUS; Cytogenetic Aberrations Present in Smoldering MM; Cytogenetic Aberrations in Symptomatic Myeloma; Chromosome 13 Aberrations; Deletions of 17p13; Chromosome 1p Deletions; 1q21 Amplification
The Origin of 1q21 Copy Number IncreasesClonal Evolution to Cytogenetically Defined High-Risk Disease; Myelodysplastic Clones; Conclusion; Acknowledgments; References; 5 Flow Cytometric Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms; FCM for Diagnosis of PCN; FCM for Identification of Biomarkers; FCM for MRD Monitoring; FCM as a Differential Diagnosis; FCM for Identification of Therapeutic Target; Summary; References; 6 Renal Manifestations of Plasma Cell Neoplasms; Introduction; Light Chain Cast Nephropathy; Light Chain Proximal Tubulopathy
Monoclonal Ig Deposition DiseaseRenal Amyloidosis; Monoclonal Gammopathy of Renal Significance; Immunofluorescence; Electron Microscopy; Tubulointerstitial Nephritis, Monoclonal Light Chain Mediated; Waldenstrom Macroglobulinemia-Associated Glomerulopathy; Conclusion; References; Index